English
简体中文
Total: £ 56.28
Published Date: 2025-03-24 | Pages: 100 | Tables: 100 | Pharma & Healthcare
The global Nuclear Medicine & Radiopharmaceuticals market size was US$ 6678 million in 2024 and is forecast to a readjusted size of US$ 10850 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.
Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.
There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.
Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.
Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.
The global Nuclear Medicine & Radiopharmaceuticals market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng
By Type: (Dominant Segment vs High-Margin Innovation)
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
By Application: (Core Demand Driver vs Emerging Opportunity)
Oncology
Thyroid
Cardiology
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Cardinal Health in Europe)
- Emerging Product Trends: Diagnostic Radiopharmaceuticals adoption vs. Therapeutic Radiopharmaceuticals premiumization
- Demand-Side Dynamics: Oncology growth in China vs. Thyroid potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Nuclear Medicine & Radiopharmaceuticals market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Therapeutic Radiopharmaceuticals in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Thyroid in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Diagnostic Radiopharmaceuticals dominance in Europe vs. Therapeutic Radiopharmaceuticals demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Nuclear Medicine & Radiopharmaceuticals Product Scope
1.2 Nuclear Medicine & Radiopharmaceuticals by Type
1.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020 & 2024 & 2031)
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapeutic Radiopharmaceuticals
1.3 Nuclear Medicine & Radiopharmaceuticals by Application
1.3.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Oncology
1.3.3 Thyroid
1.3.4 Cardiology
1.3.5 Others
1.4 Global Nuclear Medicine & Radiopharmaceuticals Market Estimates and Forecasts (2020-2031)
1.4.1 Global Nuclear Medicine & Radiopharmaceuticals Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Nuclear Medicine & Radiopharmaceuticals Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Nuclear Medicine & Radiopharmaceuticals Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Nuclear Medicine & Radiopharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Nuclear Medicine & Radiopharmaceuticals Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2020-2025)
2.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region (2020-2025)
2.3 Global Nuclear Medicine & Radiopharmaceuticals Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Nuclear Medicine & Radiopharmaceuticals Market Size and Prospective (2020-2031)
2.4.2 Europe Nuclear Medicine & Radiopharmaceuticals Market Size and Prospective (2020-2031)
2.4.3 China Nuclear Medicine & Radiopharmaceuticals Market Size and Prospective (2020-2031)
2.4.4 Japan Nuclear Medicine & Radiopharmaceuticals Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Nuclear Medicine & Radiopharmaceuticals Historic Market Review by Type (2020-2025)
3.1.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2025)
3.1.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2020-2025)
3.1.3 Global Nuclear Medicine & Radiopharmaceuticals Price by Type (2020-2025)
3.2 Global Nuclear Medicine & Radiopharmaceuticals Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Forecast by Type (2026-2031)
3.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Forecast by Type (2026-2031)
3.2.3 Global Nuclear Medicine & Radiopharmaceuticals Price Forecast by Type (2026-2031)
3.3 Different Types Nuclear Medicine & Radiopharmaceuticals Representative Players
4 Global Market Size by Application
4.1 Global Nuclear Medicine & Radiopharmaceuticals Historic Market Review by Application (2020-2025)
4.1.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2025)
4.1.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2020-2025)
4.1.3 Global Nuclear Medicine & Radiopharmaceuticals Price by Application (2020-2025)
4.2 Global Nuclear Medicine & Radiopharmaceuticals Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Forecast by Application (2026-2031)
4.2.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue Forecast by Application (2026-2031)
4.2.3 Global Nuclear Medicine & Radiopharmaceuticals Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Nuclear Medicine & Radiopharmaceuticals Application
5 Competition Landscape by Players
5.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Players (2020-2025)
5.2 Global Top Nuclear Medicine & Radiopharmaceuticals Players by Revenue (2020-2025)
5.3 Global Nuclear Medicine & Radiopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nuclear Medicine & Radiopharmaceuticals as of 2024)
5.4 Global Nuclear Medicine & Radiopharmaceuticals Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Product Type & Application
5.7 Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Nuclear Medicine & Radiopharmaceuticals Sales by Company
6.1.1.1 North America Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025)
6.1.1.2 North America Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025)
6.1.2 North America Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
6.1.3 North America Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
6.1.4 North America Nuclear Medicine & Radiopharmaceuticals Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Nuclear Medicine & Radiopharmaceuticals Sales by Company
6.2.1.1 Europe Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025)
6.2.1.2 Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025)
6.2.2 Europe Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
6.2.3 Europe Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
6.2.4 Europe Nuclear Medicine & Radiopharmaceuticals Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Nuclear Medicine & Radiopharmaceuticals Sales by Company
6.3.1.1 China Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025)
6.3.1.2 China Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025)
6.3.2 China Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
6.3.3 China Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
6.3.4 China Nuclear Medicine & Radiopharmaceuticals Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Nuclear Medicine & Radiopharmaceuticals Sales by Company
6.4.1.1 Japan Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025)
6.4.1.2 Japan Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025)
6.4.2 Japan Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
6.4.3 Japan Nuclear Medicine & Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
6.4.4 Japan Nuclear Medicine & Radiopharmaceuticals Major Customer
6.4.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Cardinal Health
7.1.1 Cardinal Health Company Information
7.1.2 Cardinal Health Business Overview
7.1.3 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Cardinal Health Nuclear Medicine & Radiopharmaceuticals Products Offered
7.1.5 Cardinal Health Recent Development
7.2 GE Healthcare
7.2.1 GE Healthcare Company Information
7.2.2 GE Healthcare Business Overview
7.2.3 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.2.4 GE Healthcare Nuclear Medicine & Radiopharmaceuticals Products Offered
7.2.5 GE Healthcare Recent Development
7.3 Jubilant Pharma
7.3.1 Jubilant Pharma Company Information
7.3.2 Jubilant Pharma Business Overview
7.3.3 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Products Offered
7.3.5 Jubilant Pharma Recent Development
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Business Overview
7.4.3 Novartis Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Novartis Nuclear Medicine & Radiopharmaceuticals Products Offered
7.4.5 Novartis Recent Development
7.5 Curium Pharma
7.5.1 Curium Pharma Company Information
7.5.2 Curium Pharma Business Overview
7.5.3 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Curium Pharma Nuclear Medicine & Radiopharmaceuticals Products Offered
7.5.5 Curium Pharma Recent Development
7.6 SIEMENS
7.6.1 SIEMENS Company Information
7.6.2 SIEMENS Business Overview
7.6.3 SIEMENS Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.6.4 SIEMENS Nuclear Medicine & Radiopharmaceuticals Products Offered
7.6.5 SIEMENS Recent Development
7.7 Lantheus
7.7.1 Lantheus Company Information
7.7.2 Lantheus Business Overview
7.7.3 Lantheus Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Lantheus Nuclear Medicine & Radiopharmaceuticals Products Offered
7.7.5 Lantheus Recent Development
7.8 Bracco Imaging
7.8.1 Bracco Imaging Company Information
7.8.2 Bracco Imaging Business Overview
7.8.3 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Products Offered
7.8.5 Bracco Imaging Recent Development
7.9 Bayer
7.9.1 Bayer Company Information
7.9.2 Bayer Business Overview
7.9.3 Bayer Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Bayer Nuclear Medicine & Radiopharmaceuticals Products Offered
7.9.5 Bayer Recent Development
7.10 Eli Lilly
7.10.1 Eli Lilly Company Information
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Eli Lilly Nuclear Medicine & Radiopharmaceuticals Products Offered
7.10.5 Eli Lilly Recent Development
7.11 Aurobindo Pharma
7.11.1 Aurobindo Pharma Company Information
7.11.2 Aurobindo Pharma Business Overview
7.11.3 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Products Offered
7.11.5 Aurobindo Pharma Recent Development
7.12 Mundipharma
7.12.1 Mundipharma Company Information
7.12.2 Mundipharma Business Overview
7.12.3 Mundipharma Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.12.4 Mundipharma Nuclear Medicine & Radiopharmaceuticals Products Offered
7.12.5 Mundipharma Recent Development
7.13 China Isotope & Radiation
7.13.1 China Isotope & Radiation Company Information
7.13.2 China Isotope & Radiation Business Overview
7.13.3 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.13.4 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Products Offered
7.13.5 China Isotope & Radiation Recent Development
7.14 Dongcheng
7.14.1 Dongcheng Company Information
7.14.2 Dongcheng Business Overview
7.14.3 Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
7.14.4 Dongcheng Nuclear Medicine & Radiopharmaceuticals Products Offered
7.14.5 Dongcheng Recent Development
8 Nuclear Medicine & Radiopharmaceuticals Manufacturing Cost Analysis
8.1 Nuclear Medicine & Radiopharmaceuticals Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Nuclear Medicine & Radiopharmaceuticals
8.4 Nuclear Medicine & Radiopharmaceuticals Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Nuclear Medicine & Radiopharmaceuticals Distributors List
9.3 Nuclear Medicine & Radiopharmaceuticals Customers
10 Nuclear Medicine & Radiopharmaceuticals Market Dynamics
10.1 Nuclear Medicine & Radiopharmaceuticals Industry Trends
10.2 Nuclear Medicine & Radiopharmaceuticals Market Drivers
10.3 Nuclear Medicine & Radiopharmaceuticals Market Challenges
10.4 Nuclear Medicine & Radiopharmaceuticals Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of Tables
Table 1. Global Nuclear Medicine & Radiopharmaceuticals Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Nuclear Medicine & Radiopharmaceuticals Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Nuclear Medicine & Radiopharmaceuticals Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) by Region (2020-2025)
Table 5. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2020-2025)
Table 6. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Region (2020-2025)
Table 8. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) Forecast by Region (2026-2031)
Table 9. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share Forecast by Region (2026-2031)
Table 12. Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (K Dose) & (2020-2025)
Table 13. Global Nuclear Medicine & Radiopharmaceuticals Sales Share by Type (2020-2025)
Table 14. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Nuclear Medicine & Radiopharmaceuticals Price by Type (US$/Dose) & (2020-2025)
Table 16. Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (K Dose) & (2026-2031)
Table 17. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Nuclear Medicine & Radiopharmaceuticals Price by Type (US$/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (K Dose) & (2020-2025)
Table 21. Global Nuclear Medicine & Radiopharmaceuticals Sales Share by Application (2020-2025)
Table 22. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Nuclear Medicine & Radiopharmaceuticals Price by Application (US$/Dose) & (2020-2025)
Table 24. Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (K Dose) & (2026-2031)
Table 25. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Nuclear Medicine & Radiopharmaceuticals Price by Application (US$/Dose) & (2026-2031)
Table 27. New Sources of Growth in Nuclear Medicine & Radiopharmaceuticals Application
Table 28. Global Nuclear Medicine & Radiopharmaceuticals Sales by Company (K Dose) & (2020-2025)
Table 29. Global Nuclear Medicine & Radiopharmaceuticals Sales Share by Company (2020-2025)
Table 30. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Company (2020-2025)
Table 32. Global Nuclear Medicine & Radiopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nuclear Medicine & Radiopharmaceuticals as of 2024)
Table 33. Global Market Nuclear Medicine & Radiopharmaceuticals Average Price by Company (US$/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Product Type & Application
Table 36. Global Key Manufacturers of Nuclear Medicine & Radiopharmaceuticals, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025) & (K Dose)
Table 39. North America Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Company (2020-2025)
Table 40. North America Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Company (2020-2025)
Table 42. North America Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2025) & (K Dose)
Table 43. North America Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2020-2025)
Table 44. North America Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2025) & (K Dose)
Table 45. North America Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2020-2025)
Table 46. Europe Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025) & (K Dose)
Table 47. Europe Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Company (2020-2025)
Table 48. Europe Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Company (2020-2025)
Table 50. Europe Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2025) & (K Dose)
Table 51. Europe Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2020-2025)
Table 52. Europe Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2025) & (K Dose)
Table 53. Europe Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2020-2025)
Table 54. China Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025) & (K Dose)
Table 55. China Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Company (2020-2025)
Table 56. China Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Company (2020-2025)
Table 58. China Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2025) & (K Dose)
Table 59. China Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2020-2025)
Table 60. China Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2025) & (K Dose)
Table 61. China Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2020-2025)
Table 62. Japan Nuclear Medicine & Radiopharmaceuticals Sales by Company (2020-2025) & (K Dose)
Table 63. Japan Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Company (2020-2025)
Table 64. Japan Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Company (2020-2025)
Table 66. Japan Nuclear Medicine & Radiopharmaceuticals Sales by Type (2020-2025) & (K Dose)
Table 67. Japan Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2020-2025)
Table 68. Japan Nuclear Medicine & Radiopharmaceuticals Sales by Application (2020-2025) & (K Dose)
Table 69. Japan Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2020-2025)
Table 70. Cardinal Health Company Information
Table 71. Cardinal Health Description and Business Overview
Table 72. Cardinal Health Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Cardinal Health Nuclear Medicine & Radiopharmaceuticals Product
Table 74. Cardinal Health Recent Development
Table 75. GE Healthcare Company Information
Table 76. GE Healthcare Description and Business Overview
Table 77. GE Healthcare Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. GE Healthcare Nuclear Medicine & Radiopharmaceuticals Product
Table 79. GE Healthcare Recent Development
Table 80. Jubilant Pharma Company Information
Table 81. Jubilant Pharma Description and Business Overview
Table 82. Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Jubilant Pharma Nuclear Medicine & Radiopharmaceuticals Product
Table 84. Jubilant Pharma Recent Development
Table 85. Novartis Company Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Novartis Nuclear Medicine & Radiopharmaceuticals Product
Table 89. Novartis Recent Development
Table 90. Curium Pharma Company Information
Table 91. Curium Pharma Description and Business Overview
Table 92. Curium Pharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Curium Pharma Nuclear Medicine & Radiopharmaceuticals Product
Table 94. Curium Pharma Recent Development
Table 95. SIEMENS Company Information
Table 96. SIEMENS Description and Business Overview
Table 97. SIEMENS Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. SIEMENS Nuclear Medicine & Radiopharmaceuticals Product
Table 99. SIEMENS Recent Development
Table 100. Lantheus Company Information
Table 101. Lantheus Description and Business Overview
Table 102. Lantheus Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 103. Lantheus Nuclear Medicine & Radiopharmaceuticals Product
Table 104. Lantheus Recent Development
Table 105. Bracco Imaging Company Information
Table 106. Bracco Imaging Description and Business Overview
Table 107. Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 108. Bracco Imaging Nuclear Medicine & Radiopharmaceuticals Product
Table 109. Bracco Imaging Recent Development
Table 110. Bayer Company Information
Table 111. Bayer Description and Business Overview
Table 112. Bayer Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 113. Bayer Nuclear Medicine & Radiopharmaceuticals Product
Table 114. Bayer Recent Development
Table 115. Eli Lilly Company Information
Table 116. Eli Lilly Description and Business Overview
Table 117. Eli Lilly Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 118. Eli Lilly Nuclear Medicine & Radiopharmaceuticals Product
Table 119. Eli Lilly Recent Development
Table 120. Aurobindo Pharma Company Information
Table 121. Aurobindo Pharma Description and Business Overview
Table 122. Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 123. Aurobindo Pharma Nuclear Medicine & Radiopharmaceuticals Product
Table 124. Aurobindo Pharma Recent Development
Table 125. Mundipharma Company Information
Table 126. Mundipharma Description and Business Overview
Table 127. Mundipharma Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 128. Mundipharma Nuclear Medicine & Radiopharmaceuticals Product
Table 129. Mundipharma Recent Development
Table 130. China Isotope & Radiation Company Information
Table 131. China Isotope & Radiation Description and Business Overview
Table 132. China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 133. China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product
Table 134. China Isotope & Radiation Recent Development
Table 135. Dongcheng Company Information
Table 136. Dongcheng Description and Business Overview
Table 137. Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 138. Dongcheng Nuclear Medicine & Radiopharmaceuticals Product
Table 139. Dongcheng Recent Development
Table 140. Production Base and Market Concentration Rate of Raw Material
Table 141. Key Suppliers of Raw Materials
Table 142. Nuclear Medicine & Radiopharmaceuticals Distributors List
Table 143. Nuclear Medicine & Radiopharmaceuticals Customers List
Table 144. Nuclear Medicine & Radiopharmaceuticals Market Trends
Table 145. Nuclear Medicine & Radiopharmaceuticals Market Drivers
Table 146. Nuclear Medicine & Radiopharmaceuticals Market Challenges
Table 147. Nuclear Medicine & Radiopharmaceuticals Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Nuclear Medicine & Radiopharmaceuticals Product Picture
Figure 2. Global Nuclear Medicine & Radiopharmaceuticals Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type in 2024 & 2031
Figure 4. Diagnostic Radiopharmaceuticals Product Picture
Figure 5. Therapeutic Radiopharmaceuticals Product Picture
Figure 6. Global Nuclear Medicine & Radiopharmaceuticals Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 7. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application in 2024 & 2031
Figure 8. Oncology Examples
Figure 9. Thyroid Examples
Figure 10. Cardiology Examples
Figure 11. Others Examples
Figure 12. Global Nuclear Medicine & Radiopharmaceuticals Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate (2020-2031) & (US$ Million)
Figure 14. Global Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) Growth Rate (2020-2031)
Figure 15. Global Nuclear Medicine & Radiopharmaceuticals Price Trends Growth Rate (2020-2031) & (US$/Dose)
Figure 16. Nuclear Medicine & Radiopharmaceuticals Report Years Considered
Figure 17. Global Market Nuclear Medicine & Radiopharmaceuticals Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 18. Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region: 2020 VS 2024
Figure 19. North America Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. North America Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) Growth Rate (2020-2031)
Figure 21. Europe Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Europe Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) Growth Rate (2020-2031)
Figure 23. China Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. China Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) Growth Rate (2020-2031)
Figure 25. Japan Nuclear Medicine & Radiopharmaceuticals Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. Japan Nuclear Medicine & Radiopharmaceuticals Sales (K Dose) Growth Rate (2020-2031)
Figure 27. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Type (2020-2025)
Figure 28. Global Nuclear Medicine & Radiopharmaceuticals Sales Share by Type (2026-2031)
Figure 29. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Type (2026-2031)
Figure 30. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Application (2020-2025)
Figure 31. Global Nuclear Medicine & Radiopharmaceuticals Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Nuclear Medicine & Radiopharmaceuticals Sales Share by Application (2026-2031)
Figure 33. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Application (2026-2031)
Figure 34. Global Nuclear Medicine & Radiopharmaceuticals Sales Share by Company (2024)
Figure 35. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Company (2024)
Figure 36. Global 5 Largest Nuclear Medicine & Radiopharmaceuticals Players Market Share by Revenue in Nuclear Medicine & Radiopharmaceuticals: 2020 & 2024
Figure 37. Nuclear Medicine & Radiopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Nuclear Medicine & Radiopharmaceuticals
Figure 39. Manufacturing Process Analysis of Nuclear Medicine & Radiopharmaceuticals
Figure 40. Nuclear Medicine & Radiopharmaceuticals Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
